<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02159287</url>
  </required_header>
  <id_info>
    <org_study_id>92-01-01-5667</org_study_id>
    <nct_id>NCT02159287</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin in Stroke</brief_title>
  <official_title>Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients With Embolic Stroke Due to Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Atrial fibrillation (AF) make a unique group of ischemic stroke, mostly caused
      by emboli from the left atrial appendage. Oral anticoagulation (Warfarin) is recommended for
      prevention of recurrent embolic stroke but it takes several days to reach a therapeutic
      international normalized ratio (INR : 2.5) so bridging therapy with a short acting
      intravenous anticoagulant is recommended until therapeutic INR level is reached. A common
      strategy is to use intravenous unfractionated heparin (UFH) until a standard activated
      partial thromboplastin time (aPTT) is reached and then initiating warfarin. Another strategy
      is to use subcutaneous (SQ) injection of a low-molecular-weight heparin (LMWH) eg.
      Enoxaparin.

      The investigators will compare LMWH and UFH, focusing on risk of new stroke and mortality
      rate.

      METHOD: This study is randomized controlled trial that will be performed in 80 patients ages
      between 18 and 75 with confirmed acute ischemic stroke purely due to AF who will be
      hospitalized in Shiraz Medical University affiliated teaching hospitals. Patients will be
      randomly assigned in two groups. A brain CT will be done to confirm the absence of
      intracranial hemorrhage and to assess the size of cerebral ischemia.

      First group will receive 1 mg of enoxaparin (Clexane, Sanofi, Paris) per kilogram of body
      weight SQ every 12 hour with warfarin 5mg orally everyday and both drugs will be continued
      until the target INR level (2.5) is reached then clexane will be discontinued.

      The second group will receive continuous UFH infusion 1000 unit per hour and then the dose
      will be adjusted to maintain a therapeutic aPTT (two times to baseline) level then warfarin
      will be started (5 mg everyday).

      The investigators will follow patients in both groups until target INR will be achieved (2.5)
      and after that clexane and UFH will be discontinued. Adverse events will be assessed in both
      groups for three months.

      Data will be analyzed with Statistical Package for the Social Sciences (SPSS) version 15 and
      Chi-square statistics.

      Main outcome of our study will be evaluation of new stroke, mortality, central nervous system
      (CNS) hemorrhage, major bleeding, drop out and other unwanted side effects in first week and
      three months after stroke.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mortality</measure>
    <time_frame>up to the 3 months of follow-up</time_frame>
    <description>all death cases are included but only mortality due to cerebrovascular accident are considered.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ischemic stroke</measure>
    <time_frame>up to the 3 months of follow-up</time_frame>
    <description>Ischemic strokes are those that are caused by interruption of the blood supply</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hemorrhagic stroke</measure>
    <time_frame>up to the 3 months of follow-up</time_frame>
    <description>hemorrhagic strokes are the ones which result from rupture of a blood vessel or an abnormal vascular structure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>symptomatic CNS hemorrhage</measure>
    <time_frame>up to the 3 months of follow-up</time_frame>
    <description>Intracranial bleeding occurs when a blood vessel within the skull is ruptured or leaks that causes neurological symptoms. It can result from nontraumatic causes as occurs in hemorrhagic stroke such as a ruptured aneurysm. Anticoagulant therapy can heighten the risk that an intracranial hemorrhage will occur.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-CNS hemorrhage</measure>
    <time_frame>up to the 3 months of follow-up</time_frame>
    <description>any bleeding of other sites of body except CNS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>asymptomatic CNS_hemorrhage</measure>
    <time_frame>up to the 3 months of follow-up</time_frame>
    <description>Intracranial bleeding occurs when a blood vessel within the skull is ruptured or leaks that will not cause neurological symptoms. It can result from nontraumatic causes as occurs in hemorrhagic stroke such as a ruptured aneurysm. Anticoagulant therapy can heighten the risk that an intracranial hemorrhage will occur.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to reach target INR</measure>
    <time_frame>average time 7 to 10 days (it is variable between individuals)</time_frame>
    <description>the therapeutic INR level for patients on warfarin therapy is between 2.0 to 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tolerability of drugs</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 1 week</time_frame>
    <description>tolerability is how a patient can tolerate heparin and LMWH in terms of side effect and route of administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Embolic Stroke</condition>
  <arm_group>
    <arm_group_label>Low molecular-weight heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>these patients will receive 1 mg of enoxaparin (clexane) per kilogram of body weight subcutaneous every 12 hour with warfarin 5mg QD and both drugs will be continued until the target INR level (2.5) is reached then clexane will be discontinued.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>unfractionated heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive continuous intravenous unfractionated heparin sodium infusion 1000 unit per hour initially and then the dose will be adjusted to maintain a therapeutic aPTT level (two times to baseline) then warfarin will be started (5 mg QD).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>1 mg of enoxaparin per kilogram of body weight subcutaneous every 12 hour</description>
    <arm_group_label>Low molecular-weight heparin</arm_group_label>
    <other_name>clexane (Clexane, Sanofi, Paris)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>1000 unit per hour continuous intravenous infusion of heparin sodium</description>
    <arm_group_label>unfractionated heparin</arm_group_label>
    <other_name>Heparin Sodium (Alborz Darou,Tehran)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  confirmed diagnosis of acute ischemic stroke purely due to AF

          -  AF confirmed by ECG or 24 hour holter monitoring

          -  patients who need initiation of anticoagulation for prevention of recurrent stroke

        Exclusion Criteria:

          -  ages less than 18 or more than 75

          -  no cooperation

          -  CNS hemorrhage

          -  major bleeding

          -  infarction size of more than one third of middle cerebral artery territory

          -  National Institutes of Health Stroke Scale (NIHSS) more than 20

          -  hypersensitivity to IV UFH or LMWH

          -  no informed consent

          -  other causes for stroke except AF

          -  pregnancy

          -  breast feeding

          -  uncontrolled hypertension (BP more than 220/120)

          -  renal, hepatic, respiratory or cardiac failure

          -  myocardial infarction

          -  infectious endocarditis

          -  coma

          -  vasculitis

          -  dissection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Afshin Borhani Haghighi, Associate professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shiraz University of medical sciences, department of neurology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Farnia Feiz, medical student</last_name>
    <role>Study Chair</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reyhane Sedghi, medical student</last_name>
    <role>Study Chair</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Afshin Borhani-Haghighi, Associate professor</last_name>
    <phone>00989177029134</phone>
    <email>Aborhani@sums.ac.ir</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nemazi hospital</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <zip>11351-71937</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reyhane Sedghi, MD</last_name>
      <phone>00989177035783</phone>
      <email>reihaneh.sedghi@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faghihi hospital</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <zip>7134844119</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farnia Feiz, MD</last_name>
      <phone>00989177383403</phone>
      <email>farniafeiz@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Shahpouri MM, Mousavi S, Khorvash F, Mousavi SM, Hoseini T. Anticoagulant therapy for ischemic stroke: A review of literature. J Res Med Sci. 2012 Apr;17(4):396-401.</citation>
    <PMID>23267405</PMID>
  </reference>
  <reference>
    <citation>Kase CS, Albers GW, Bladin C, Fieschi C, Gabbai AA, O'Riordan W, Pineo GF; PREVAIL Investigators. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke. 2009 Nov;40(11):3532-40. doi: 10.1161/STROKEAHA.109.555003. Epub 2009 Aug 20.</citation>
    <PMID>19696423</PMID>
  </reference>
  <reference>
    <citation>Algra A, de Schryver EL, van Gijn J, Kappelle LJ, Koudstaal PJ. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev. 2001;(4):CD001342. Review. Update in: Cochrane Database Syst Rev. 2006;(3):CD001342.</citation>
    <PMID>11687110</PMID>
  </reference>
  <reference>
    <citation>Saxena R, Lewis S, Berge E, Sandercock PA, Koudstaal PJ. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke. 2001 Oct;32(10):2333-7.</citation>
    <PMID>11588322</PMID>
  </reference>
  <reference>
    <citation>Hallevi H, Albright KC, Martin-Schild S, Barreto AD, Savitz SI, Escobar MA, Gonzales NR, Noser EA, Illoh K, Grotta JC. Anticoagulation after cardioembolic stroke: to bridge or not to bridge? Arch Neurol. 2008 Sep;65(9):1169-73. doi: 10.1001/archneur.65.9.noc70105. Epub 2008 Jul 14.</citation>
    <PMID>18625852</PMID>
  </reference>
  <reference>
    <citation>Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schu√ºnemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):7S-47S. doi: 10.1378/chest.1412S3. Erratum in: Chest. 2012 Apr;141(4):1129. Dosage error in article text. Chest. 2012 Dec;142(6):1698. Dosage error in article text.</citation>
    <PMID>22315257</PMID>
  </reference>
  <reference>
    <citation>Fahimi F, Baniasadi S, Behzadnia N. Enoxaparin Utilization Evaluation: An Observational Prospective Study in Medical Inpatients. Iranian Journal of Pharmaceutical Research 2008;7 (1):77-82.</citation>
  </reference>
  <reference>
    <citation>Kalafut MA, Gandhi R, Kidwell CS, Saver JL. Safety and cost of low-molecular-weight heparin as bridging anticoagulant therapy in subacute cerebral ischemia. Stroke. 2000 Nov;31(11):2563-8.</citation>
    <PMID>11062276</PMID>
  </reference>
  <reference>
    <citation>Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EF; American Heart Association; American Stroke Association Stroke Council; Clinical Cardiology Council; Cardiovascular Radiology and Intervention Council; Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007 May;38(5):1655-711. Epub 2007 Apr 12. Erratum in: Stroke. 2007 Jun;38(6):e38. Stroke. 2007 Sep;38(9):e96.</citation>
    <PMID>17431204</PMID>
  </reference>
  <reference>
    <citation>Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997 Aug 14;337(7):447-52.</citation>
    <PMID>9250846</PMID>
  </reference>
  <reference>
    <citation>Burak CR, Bowen MD, Barron TF. The use of enoxaparin in children with acute, nonhemorrhagic ischemic stroke. Pediatr Neurol. 2003 Oct;29(4):295-8.</citation>
    <PMID>14643390</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2014</study_first_posted>
  <last_update_submitted>June 6, 2014</last_update_submitted>
  <last_update_submitted_qc>June 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiraz University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Afshin Borhani-Haghighi</investigator_full_name>
    <investigator_title>Associate Professor of Neurology Shiraz University of Medical Sciences</investigator_title>
  </responsible_party>
  <keyword>ischemic stroke</keyword>
  <keyword>atrial fibrillation</keyword>
  <keyword>bridging therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 3, 2017</submitted>
    <returned>September 22, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

